High-dose, short-course radiation for prostate cancer does not increase side effects

Nov 01, 2010

When treating prostate cancer with radiation therapy, side effects such as urinary problems and rectal pain and bleeding are a concern, as is impact on the patient's overall quality of life. So when new, more efficient treatment methods are developed, one important question is whether better treatment comes at the cost of increased side effects and decreased quality of life.

In the case of short-course, high-dose (hypofractionated) radiation therapy, the answer is no, according research at Fox Chase Cancer Center led by Aruna Turaka, M.D., radiation oncologist at Fox Chase. Turaka will present the results on November 2nd at the annual meeting of the American Society for Radiation .

Turaka and colleagues compared two groups of prostate cancer patients treated with intensity-modulated (IMRT), a technique that uses multiple beams of varying intensities to precisely radiate tumors while minimizing exposure to healthy, adjacent tissues. One group received conventional IMRT; the other group was treated with hypofractionated IMRT, which delivers a higher total dose of radiation in fewer sessions.

The patients—a total of 307 men randomly assigned to one or the other treatment group—were given quality of life assessments at the beginning of treatment and six, 12, and 24 months later. They were also evaluated at the same timepoints for genitourinary and gastrointestinal problems.

"We found no significant differences between the two groups," says Turaka. "Hypofractionated IMRT not only decreases the treatment duration—26 days compared to 38 days for conventional IMRT—but it also allows us to deliver a higher total dosage. Our results tell us that we can achieve these higher dosages with no change in side effect profile or quality of life."

Longer follow-up is needed to draw conclusions about the relative efficacy of regular and hypofractionated IMRT in treating , Turaka says.

Explore further: Survival differences seen for advanced-stage laryngeal cancer

add to favorites email to friend print save as pdf

Related Stories

Facts About Prostate Cancer and Its Treatment

Oct 25, 2006

In 2006, about 235,000 Americans will be diagnosed with prostate cancer, making it the most common cancer among males. If caught early, prostate cancer is very treatable and usually curable.

Recommended for you

Survival differences seen for advanced-stage laryngeal cancer

20 hours ago

The five-year survival rate for advanced-stage laryngeal cancer was higher than national levels in a small study at a single academic center performing a high rate of surgical therapy, including a total laryngectomy (removal ...

Gene test aids cancer profile

Nov 27, 2014

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.